correct patrolly, new ph2 trials for head and neck cancer and nsclc are
a supply only deal with Merck with Immutep controlling trials, Merck
supplying keytruda only...target 109 patients, keytruda market value
for 109 by $150,000 per patient = $16.5M USD per annum....
Merck are the likely candidate for a deal of sorts in my book..
correct patrolly, new ph2 trials for head and neck cancer and...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.8¢ | 30.3¢ | $544.1K | 1.751M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 84058 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 518277 | 39 |
View Market Depth
| Last trade - 13.38pm 27/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
